Ge Long Hui·2025-12-08 09:39Core Viewpoint - Shanghai Pharmaceuticals (02607.HK) announced that its drug, Amisulpride Orally Disintegrating Tablets, has been successfully included in the National Medical Insurance Catalog, effective from January 1, 2026, following negotiations with the National Healthcare Security Administration and the Ministry of Human Resources and Social Security [1] Group 1: Drug Information - Amisulpride Orally Disintegrating Tablets is a modified formulation of Amisulpride, originally launched by Sanofi in France in 1986, used for treating adult schizophrenia [1] - Shanghai Pharmaceuticals' subsidiary, Shanghai Shiyou Zhongxi Pharmaceutical Co., Ltd., became the marketing authorization holder for Amisulpride Orally Disintegrating Tablets after approval from the National Medical Products Administration in October 2025 [1] - As of the announcement date, there are no other companies in China that have listed Amisulpride Orally Disintegrating Tablets [1] Group 2: Market Data - According to the IQVIA database, the hospital procurement amount for Amisulpride oral formulations in 2024 is projected to be RMB 168.41 million [1]